| Metric | Value ($ M) |
|---|---|
| Revenue | 1.00 |
| Total Income | 1.00 |
| Expenditure | 108.66 |
| PBT | -111.34 |
| Net Profit | -111.46 |
| OPM | — |
| NPM | — |
| EPS | -1.77 |
Zenas BioPharma Reports Q2 2026 Financial Results and Provides Corporate Update
13 Aug 2026 · 13 Aug, 4:40 pm
Summary
Zenas BioPharma reported its financial results for the second quarter ended June 30, 2026, with revenue of $1.0 million primarily from a development milestone. The company's cash, cash equivalents, and investments stood at $673.9 million. Operating expenses increased, with R&D expenses at $62.9 million and G&A expenses at $15.7 million, alongside $30.0 million in acquired in-process R&D expenses. This resulted in a net loss of $111.5 million for the quarter. Key corporate updates include the FDA's acceptance of the obexelimab BLA for IgG4-RD, with a target action date of May 27, 2027, and the expected reporting of topline data for obexelimab in SLE and initial data for ZB021 by year-end.
Key Highlights
- 1
Zenas BioPharma reported revenue of $1.0 million for the quarter ended June 30, 2026, related to a development milestone.
- 2
The company's cash, cash equivalents and investments totaled $673.9 million as of June 30, 2026.
- 3
Research and development expenses increased to $62.9 million for the quarter ended June 30, 2026, compared to $43.0 million in the prior year period.
- 4
General and administrative expenses rose to $15.7 million for the quarter ended June 30, 2026, from $12.1 million in the prior year period.
- 5
Acquired in-process research and development expenses were $30.0 million for the quarter ended June 30, 2026.
- 6
Net loss for the quarter ended June 30, 2026, was $111.5 million, compared to a net loss of $52.2 million for the quarter ended June 30, 2025.
- 7
The FDA accepted the Biologics License Application (BLA) for obexelimab for the treatment of IgG4-Related Disease (IgG4-RD), with a PDUFA target action date of May 27, 2027.
Management Comments
Lonnie Moulder
2026 continues to be a transformative year for Zenas, highlighted by FDA acceptance of the obexelimab BLA for the treatment of IgG4-RD, with a PDUFA date of May 27, 2027. Our expanding team is actively preparing for the potential commercialization of our first product. The strength of the Phase 3 INDIGO data for obexelimab in IgG4-RD was underscored by its selection as an oral presentation at EULAR and simultaneous publication in the New England Journal of Medicine. Beyond IgG4-RD, we are on track to report Phase 2 topline data for obexelimab in SLE and initial Phase 1 data for ZB021 by year-end. We continue to execute across our portfolio and make meaningful progress toward our vision of becoming a fully integrated, global development and commercial-stage biopharmaceutical company that brings impactful treatments to patients living with autoimmune and chronic inflammatory diseases. We are pleased to welcome Christy to our Board of Directors as Zenas advances toward becoming a commercial-stage company. Christy has spent her career building the organizations and capabilities that bring important new medicines to patients and leading the business units behind multiple successful launches. She has since served as a director of numerous public late-stage clinical- and commercial-stage biotechnology companies. Her experience complements our board as we work to deliver potentially transformative therapies to patients with autoimmune and chronic inflammatory diseases. I would like to thank Jennifer Fox, who has played an instrumental role in the development and execution of our growth strategy over the past several years, as we successfully executed several substantial capital raising transactions and significantly expanded our R&D pipeline. I look forward to her future contributions and working with her as a strategic advisor.
Informational and educational content only. Not investment advice.